FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular, to a new antibody specifically binding to lysyl-tRNA synthetase, usable in medicine. More specifically, the invention allows for an antibody capable of specifically binding to the N-terminal domain of the lysyl-tRNA synthetase enzyme (KRS, lysyl-tRNA synthetase) exposed on extracellular membrane.
EFFECT: antibody can be used in treating or diagnosing cancer, metastases in cancer, or diseases associated with immune cell migration.
26 cl, 13 ex, 13 tbl, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| ANTIBODY SPECIFICALLY BINDING TO N-TERMINAL REGION OF LYSYL-TRNA-SYNTHETASE EXPOSED ON CELL MEMBRANE | 2018 |
|
RU2739393C1 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
